Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Gold Prices Rise on Weaker Dollar and Ceasefire Hopes 
Bank of America Maintains Forecast for Two Fed Rate Cuts in 2026 Despite Inflation Risks 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Asia FX Weekly Gains Hold Amid U.S. Inflation Data and Iran Ceasefire Uncertainty 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Oil Prices Rebound as Hormuz Disruptions and Middle East Tensions Rattle Markets 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Asian Markets Retreat as Gulf Crisis Fuels Oil Surge and Inflation Fears 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Middle East Conflict Threatens Global Economic Stability, World Bank Warns 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Trump Claims Oil Tankers Heading to U.S. Amid Iran War and Strait of Hormuz Crisis 
Trump Slams Iran Over Strait of Hormuz Oil Restrictions Amid Fragile Ceasefire 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Gold Prices Dip Amid Middle East Uncertainty and Inflation Fears 
Samsung Biologics signed a new deal with GSK, formerly GlaxoSmithKline. This will be their second manufacturing deal, and this time the agreement value is $296.1 million.
The amount is said to be almost 30% of the full-year revenue of Samsung last year, which was KRW1.5 trillion or around $1 billion, and the contract with GSK is in effect until the end of 2030. Samsung Biologics is currently the top Contract Manufacturing Organization in the world in terms of capacity, and its latest deal with the said British pharmaceutical industry company is for the supply of biopharma products.
Samsung Biologics and GSK plc confirmed their second collaborative contract late last week. As per The Korea Economic Daily, the biotech unit of the Samsung Group did not disclose the details of the exact products it will make for GSK under their contract.
One of their earlier deals was signed in May 2020, and it was a contract worth $231 million. It was also for the supply of biopharma products for eight years since the contract was made official. To be more specific, this was for the production and delivery of GSK’s Benlysta (belimumab) drug, which is used for the treatment of the autoimmune disease - lupus nephritis.
GSK and Samsung Biologics expanded their deal and signed another contract in August 2020, which was worth $368.1 million. It was a CMO agreement to produce sotrovimab, a SARS-CoV-2 monoclonal antibody that targets the COVID-19 virus.
In any case, the new deal is a remarkable expansion of the business relationship between Samsung Biologics and GSK. They already partnered in several projects, and now larger contracts are coming up
Meanwhile, Fierce Pharma reported that the new agreement comes as Samsung Biologics launches its “Super Plant,” which is also its fourth manufacturing facility. It sits in the company’s huge complex in Incheon, South Korea. It has invested more than $2 billion in the construction of this massive plant as part of its ambitious plan to become a major global player in the contract development and manufacturing organization scene.
